THE NCI-60 PANEL

Cell lines with an inconclusive p53 status are shown in red.

more information can be found here: Berglind et al., in press: download the manuscript

Cell line	ATCC number	DNA	Protein	ref	consensus	comment
LYMPHOMA LEUKEMIA
CCRF-CEM	CCL-119		R248Q	1018	R175H+R248Q	Two mutations in separate alleles
		c.524G>A, c.743G>A	R175H+R248Q	3
		c.524G>A, c.743G>A	R175H+R248Q	2249
HL-60	CCL-240		R248L	1018	p53 null
		null	p.M1_*394del	3000
		null	p.M1_*394del	2249
K-562	CCL-243	c.406_407insC	p.Q136fs*13	269	p.Q136fs*13	p53 RNA and protein are undetectable in this cell line
		c.406_407insC	p.Q136fs*13	2249
MOLT-4	CRL-1582	wt		3	Inconclusive	The status of MOLT-4 is highly heterogeneous in the literature. The report of a wt status could be due to the fact that only exons 5 to 8 (residues 126-306) were screened in several publications
		wt		1018
		c.331C>G	L111V	2242
		c.743G>A	R248Q	27
		c.916C>T	R306X	2249
RPMI-8226	CCL-155		R285L	1018	E285K	This mutant is temperature-sensitive
		c.853G>A	E285K	2249
		c.853G>A	E285K	98
SR	CRL-2262	wt		1018	wt
		wt		2249
NSCLC
A549	CCL-185	wt		1018	wt
		wt		16
		wt		2249
EKVX		del187-224 (exon 6)		1018	Inconclusive	Possible splicing defect. See below for more information
		c.609_610GG>TT	p.V203_E204>V	2249
HOP-62			Ins 212-225	1018		See below for more explanation
		c.673-2A>G  (splice junction)	p.?	2249
HOP-92			p.R175L	1018	R175L
		c.524G>T	p.R175L	2249
NCI-H226	CRL-5826		P309A	1018	Inconclusive
		c.473G>T	R158L	92
			wt	2249
NCI-H23	CRL-5800	c.738G>C	R246I	17	R246I
			R246I	1018
		c.738G>C	R246I	2249
NCI-H322M		c.743G>T	R248L	92	R248L
			R248L	1018
		c.743G>T	R248L	2249
NCI-H460	HTB-177	wt		1018	wt
		wt		2249
NCI-H522	CRL-5810		191delG	1018	p.P191fs*57
		c.572_572delC	p.P191fs*57	2249
		c.572_572delC	p.P191fs*58	92
COLON
COLO-205	CCL-222		G266E	1018	Inconclusive
		c.308_333>TA	p.Y103_L111>L	492
		c.308_333>TA	103del27	2249
HCC-2998			R213X	1018	R213X
		c.637C>T	R213X	2249
HCT-116	CCL-247	wt		1018	wt
		wt		2249
HCT-15	CCL-225	c.722C>T, c.1101-2A>C  (splice junction)	p.S241F, p.?	2249	Inconclusive
			P153A	1018
		c.722C>T	S241F	2251
HT-29	HTB-38	c.818G>A	R273H	492	R273H
		c.818G>A	R273H	2249
KM12			H179R	1018	Inconclusive
		c.215delG	p.R72fs*51	2249
SW620	CCL-227	c.818G>A, c.925C>T	R273H, P309S	9	R273H + P309S	SW480 and SW620 are derived from the same individual with a similar p53 alteration. The P309S mutation is not always reported
			R273H	1018
		c.818G>A, c.925C>T	R273H, P309S	2249
CENTRAL NERVOUS SYSTEN
SF268		c.818G>A	R273H	664	R273H
			R273H	1018
		c.818G>A	R273H	2249
SF295			p.R248Q	1018	R248Q
		c.743G>A	p.R248Q	2249
SF539		wt		1018	Inconclusive
		c.1024delC	p.R342fs*3	2249
SNB75			E258K	1018	E258K
		c.772G>A	E258K	2249
U251/SNB19		c.818G>A	R273H	632	R273H
			R273H	1018
		c.818G>A	R273H	2249
MELANOMA
LOXIMV1		wt		1018	wt
		wt		2249
Malme-3M	HTB-64	wt		1018	wt
		wt		2249
M14			G266E	1018	G266E
		c.797G>A	G266E	2249
SK-MEL-2	HTB-68		G245S	1018	G245S
		c.733G>A	G245S	2249
SK-MEL-28	HTB-72	c.434_435TG>GT	L145R	2249	L145R
		c.434T>G	L145R	1570
			C145V	1018
SK-MEL-5	HTB-70	wt		1018	wt
		wt		2249
UACC-257		wt		1018	wt
		wt		2249
UACC-62		wt		1018	wt
				2249
MDA-MB-435			G266E	1018	G266E	This cell line was originally reported as a breast carcinoma cell line but recent SNP analysis indicates that it is similar to the M14 melanoma cell line
		c.797G>A	G266E	2029
		c.797G>A	G266E	2249
MDA-N			G266E	1018	G266E	This cell line was originally reported as a breast carcinoma cell line but recent SNP analysis indicates that it is similar to the M14 melanoma cell line.  It is a derivative of MDA-MB-435 tranfected with a plasmid expressing erbB2
OVARY
IGROV1		wt		1018	Inconclusive
		wt		606
		c.377A>G	Y126C	2249
OVCAR-3	HTB-161	c.743G>A	R248Q	144	R248Q
			R248Q	1018
		c.743G>A	R248Q	2249
OVCAR-4		wt		1018	Inconclusive
		c.388C>G	L130V	2249
OVCAR-5			ins224	1018	Inconclusive
		wt		2249
OVCAR-8		c.376-1G>A		2249	Splicing defect	See below for more explanation
			del 126-132	1018
NCI/ADR-RES		c.376-1G>A		2249	Splicing defect	Originally named MCF-7/AdrR cells,  later re-designated NCI/ADR-RES.  Was recently found to be identical to OVCAR-8
			del 126-132	1018
			126del21	983
SK-OV-3	HTB-77		H179R	1018	Inconclusive	p53 RNA and protein are undetectable in this cell line: see below for more explanation
		c.267delC	p.S90fs*33	2249
RENAL
786-0	CRL-1932		P278A	1018	Inconclusive
		c.832C>G, c.560-2A>G  (splice junction)	p.P278A, p.?	2249
A498	HTB-44	wt		1018	wt
		wt		2249
ACHN	CRL-1611	wt		1018	wt
		wt		2249
CAKI-1	HTB-46	wt		1018	wt
		wt		2249
RXF393			R175H	1018	R175H
		c.524G>A	R175H	2249
SN12C			E336X	1018	E336X
		c.1006G>T	E336X	2249
TK10			L264R	1018	L264R
		c.791T>G	L264R	2249
U031		wt		1018	wt
		wt		2249
PROSTATE
DU-145	HTB-81		P223L	1018	P223L + V274F	See below for more explanation
		c.820G>T	V274F	2249
		c.668C>T + c.820G>T	P223L + V274F	3001
		c.668C>T + c.820G>T	P223L + V274F	59
PC-3	CRL-1435	c.414delC	p.K139fs*31	2249	p53 RNA and protein are undetectable in this cell line
			138del	1018
		c.414delC	138del	59
BREAST
BT-549	HTB-122	c.747G>C	R249S	24	R249S
			R249S	1018
		c.747G>C	R249S	2249
Hs 578T	HTB-126	c.469G>T	V157F	76	V157F
		c.469G>T	V157F	2249
			D157E	1018
MCF7	HTB-22	wt		1018	wt
		wt		249
MDA-MB-231	HTB-26	c.839G>A	R280K	24	R280K
			R280K	1018
T47D	HTB-133	c.580C>T	L194F	9	L194F
		c.580C>T	L194F	1018

In EKVX, the deletion of codon 187 to 224 detected on RNA-based analysis (ref 1018) corresponds exactly to the deletion of the entire exon 6, a strong argument for a splicing defect. Genomic analysis did not reveal a splicing defect but a tandem mutation at codons 203 and 204 in exon 6 (ref 2049). If the two cell lines analysed were really EKVX, this result suggests that a mutation at either codon 203 and/or 204 could affect p53 gene splicing

In OVCAR-8, the 126-132 deletion detected by the RNA-based assay (ref 1018) concerns the first six residues of exon 5. Genomic analysis (ref 2049) described a mutation in the acceptor site of exon 5 and a splicing defect leading to a shift of the normal donor site of exon 5 that skips 18 nucleotides (6 aa residues) in exon 5. Examination of the DNA sequence at codon 132 reveals an AG dinucleotide sequence preceded by a pyrimidine tract similar to those found in the splice donor sequence. The same situation is observed for NCI/ADR- RES that has been recently shown to be an ovarian carcinoma cell line originating from the same patient as OVCAR-8.

In HOP-62, RNA-based analysis (ref 1018) detected an insertion between codon 212-225 but no information about the insertion sequence was available. Codon 225 is at the boundary of exon 6 and intron 6 suggesting a splicing defect, as analysis at the genomic level (ref 2049) confirms the presence of a splice mutation in the acceptor signal of exon 6

In the majority of publications, the p53 status of the SK-OV-3 cell line is stated as “p53 null”. In fact, close examination of the original manuscript shows that the p53 gene in SK-OV-3 is not deleted and did not sustain any gross rearrangement but neither p53 RNA or protein are found. In these publications, no p53 mutations were found but the recent analysis performed at the Sanger Institute detected a deletion of a single nucleotide at position 267 (codon 90) (Ikediobi et al., 2006). It is therefore possible that nonsense-mediated mRNA decay (NMD) eliminates p53 aberrant mRNA. NMD has been observed in the human leukaemia cell line K562 where p53 is also inactivated via a 1 base pair insertion at nucleotide 136

Cell lines with a controversial p53 status Pos: Codon position (1 to 393); WT: Normal base sequence of the codon in which the mutation occurred; Mut Sequence of the mutated codon. If the mutation is a deletion or an insertion, it is indicated by "del" or "ins" followed by the number of deleted or inserted bases. The position in the codon is indicated by “a”, “b”, or “c” for the first, second or third base of the codon respectively. Example: "del66b" is a deletion of 66 bases including the second base of the codon; "ins4a" is an insertion of 4 bases occurring between the first and the second base of the codon. Label a, b, or c is omitted if the boundary of the deletion or insertion is unknown AA: Wild type amino acid; Mut: Mutant amino acid. Stop: nonsense mutation: Fs.: Frameshift mutation: InF: In-frame insertion or deletion; Comp: complexity of the mutation: SM: Single mutational event in the tumor; DMU (Double Mutation Unknown): Two p53 mutations in the same tumor but their allelique distribution is unknown; DMD (Double Mutation Different allele): Two p53 mutations in the same tumor on two different p53 alleles; DMS (Double Mutation Same allele): Two p53 mutations in the same tumor on the same p53 allele: MM (Multiple Mutation): More than two p53 mutations in the same tumor; NB: Number of tumors with this particular mutant in the database; Ref: reference number; Comments: information; More information is available in the handbook Table of references (available also in the handbook) Pos. WT Mut       AA Mut Comp Name NB Cancer Ref Comments 237 ATG ATA Met Ile SM WI-L2-NS 123 B-cell Leukemia 637 Controversy with other publications 330 CTT CAT Leu His SM WI-L2-NS 4 B-cell Leukemia 769 Controversy with other publications 126 TAC TAG Tyr Stop SM EJ 14 Bladder carcinoma 689 Controversy with other publications 164 AAG GAG Lys Glu SM EJ 25 Bladder carcinoma 729 Controversy with other publications 76 GCA del76 Ala Fs. SM FHS 738B1 1 Bladder carcinoma 561 Single report 365 CAC CGC His Arg SM HT-1197 1 Bladder carcinoma 561 wt in COSMIC 250 CCC CTC Pro Leu SM HT-1376 53 Bladder carcinoma 561 Confirmed in two other publications 261 AGT del137 Ser Fs. DMU J82 1 Bladder carcinoma 2249 Controversy with other publications Deletion of exon 8 271 GAG AAG Glu Lys MM J82 38 Bladder carcinoma 561 Controversy with other publications undocumented 4th mutation (deletion 210 bp) 271 GAG AAG Glu Lys MM J82 38 Bladder carcinoma 729 Controversy with other publications 274 GTT TTT Val Phe MM J82 32 Bladder carcinoma 561 Controversy with other publications undocumented 4th mutation (deletion 210 bp) 274 GTT TTT Val Phe MM J82 32 Bladder carcinoma 729 Controversy with other publications 320 AAG AAC Lys Asn MM J82 5 Bladder carcinoma 561 Controversy with other publications undocumented 4th mutation (deletion 210 bp) 320 AAG AAC Lys Asn DMU J82 5 Bladder carcinoma 2249 Controversy with other publications 320 AAG AAC Lys Asn MM J82 5 Bladder carcinoma 729 Controversy with other publications 183 TCA TGA Ser Stop DMU RT-112 29 Bladder carcinoma 2249 Controversy with other publications 248 CGG CAG Arg Gln SM RT-112 883 Bladder carcinoma 1733 Controversy with other publications 248 CGG CAG Arg Gln DMU RT-112 883 Bladder carcinoma 2249 Controversy with other publications 110 CGT CTT Arg Leu SM SD 28 Bladder carcinoma 294 Controversy with other publications 116 TCT TGT Ser Cys SM SD 3 Bladder carcinoma 689 Controversy with other publications 126 TAC TAG Tyr Stop SM T-24 14 Bladder carcinoma 689 Controversy with other publications 126 TAC del3a Tyr InF SM T-24 1 Bladder carcinoma 561 Controversy with other publications 126 TAC TAG Tyr Stop DMU VM-CUB-1 14 Bladder carcinoma 2249 Controversy with other publications 175 CGC CAC Arg His SM VM-CUB-1 1187 Bladder carcinoma 689 Controversy with other publications 175 CGC CAC Arg His DMU VM-CUB-1 1187 Bladder carcinoma 2249 Controversy with other publications 158 CGC CTC Arg Leu DMU VM-CUB-2 92 Bladder carcinoma 689 Controversy with other publications 158 CGC CTC Arg Leu SM VM-CUB-2 92 Bladder carcinoma 294 Controversy with other publications 163 TAC TGC Tyr Cys DMU VM-CUB-2 140 Bladder carcinoma 689 Controversy with other publications 246 ATG del1c Met Fs. SM BT-483 1 Breast carcinoma 2029 Controversy with other publications 246 ATG ATA Met Ile SM BT-483 33 Breast carcinoma 2091 Controversy with other publications 204 GAG ins7c Glu Fs. SM MDA-MB-436 1 Breast carcinoma 2029 Controversy with other publications 273 CGT CAT Arg His SM MDA-MB-436 780 Breast carcinoma 1367 Controversy with other publications 213 CGA TGA Arg Stop SM DAUDI 306 Burkitt lymphoma 44 Controversy with other publications 266 GGA GAA Gly Glu SM DAUDI 74 Burkitt lymphoma 2249 Controversy with other publications 158 CGC CAC Arg His SM ST486 105 Burkitt lymphoma 44 Consensus based on three puublications. Controversy with other publications Second mutation found by COSMIC 158 CGC CAC Arg His DMU ST486 105 Burkitt lymphoma 2249 Controversy with other publications. Excluded from the consensus 239 AAC GAC Asn Asp DMU ST486 53 Burkitt lymphoma 2249 Controversy with other publications. Excluded from the consensus 234 TAC TGC Tyr Cys SM CaR-1 133 Colorectal carcinoma 1006 Controversy with other publications. wt in COSMIC 272 GTG ATG Val Met SM CaR-1 105 Colorectal carcinoma 2051 Controversy with other publications. wt in COSMIC 103 TAC del27 Tyr InF SM COLO-205 1 Colorectal carcinoma 492 Controversy with other publications 266 GGA GAA Gly Glu SM COLO-205 74 Colorectal carcinoma 1018 Controversy with other publications 153 CCC GCC Pro Ala SM HCT-15 5 Colorectal carcinoma 1018 Controversy with other publications 241 TCC TTC Ser Phe SM HCT-15 101 Colorectal carcinoma 2251 Controversy with other publications 72 CCC del1b Pro Fs. SM KM12 1 Colorectal carcinoma 2249 Controversy with other publications 179 CAT CGT His Arg SM KM12 146 Colorectal carcinoma 1018 Controversy with other publications 156 CGC del1a Arg Fs. DMU RL95-2 3 Endometrial tumor 1625 Controversy with other publications 218 GTG del3 Val InF SM RL95-2 2 Endometrial tumor 64 Controversy with other publications 218 GTG del3a Val InF DMU RL95-2 3 Endometrial tumor 1625 Controversy with other publications 179 CAT CGT His Arg SM KYSE-450 146 Esophageal SCC 634 Controversy with other publications 339 GAG TAG Glu Stop SM KYSE-450 12 Esophageal SCC 2249 Controversy with other publications 241 TCC del32c Ser Fs. SM KYSE-510 1 Esophageal SCC 634 Controversy with other publications 343 GAG TAG Glu Stop SM KYSE-510 5 Esophageal SCC 2249 Controversy with other publications 110 CGT CTT Arg Leu SM TE-11 28 Esophageal SCC 1006 Controversy with other publications. wt in COSMIC 237 ATG ATT Met Ile SM TE-11 52 Esophageal SCC 1144 Controversy with other publications. wt in COSMIC 251 ATC CTC Ile Leu DMU MKN-74 5 Gastric carcinoma 1006 Controversy with other publications. wt in COSMIC 251 ATC CTC Ile Leu SM MKN-74 5 Gastric carcinoma 94 Controversy with other publications. wt in COSMIC 271 GAG GCG Glu Ala DMU MKN-74 3 Gastric carcinoma 1006 Controversy with other publications. wt in COSMIC 342 CGA del1a Arg Fs. SM SF-539 5 Gliomas 2249 Controversy with other publications 277 TGT del30 Cys InF SM UM-SCC-14 2 Head and Neck SCC 1019 Controversy with other publications 277 TGT del30 Cys InF DMU UM-SCC-14 2 Head and Neck SCC 1636 Controversy with other publications 280 AGA AGT Arg Ser DMU UM-SCC-14 14 Head and Neck SCC 1636 Controversy with other publications 244 GGC GCC Gly Ala SM HLE 10 Hepatocellular carcinoma 1069 Controversy with other publications 249 AGG AGC Arg Ser SM HLE 34 Hepatocellular carcinoma 230 Controversy with other publications 272 GTG ATG Val Met SM HLE 105 Hepatocellular carcinoma 1006 Controversy with other publications 237 ATG AAG Met Lys DMU SK-LMS-1 11 Leyomyosarcoma 2198 Controversy with other publications 245 GGC AGC Gly Ser SM SK-LMS-1 440 Leyomyosarcoma 14 Controversy with other publications 245 GGC AGC Gly Ser DMU SK-LMS-1 440 Leyomyosarcoma 2198 Controversy with other publications 175 CGC CAC Arg His DMU SK-UT-1 1187 Leyomyosarcoma 2249 Controversy with other publications 175 CGC CAC Arg His SM SK-UT-1 1187 Leyomyosarcoma 14 Controversy with other publications 248 CGG CAG Arg Gln DMU SK-UT-1 883 Leyomyosarcoma 2249 Controversy with other publications 187 GGT del111 Gly InF SM EKVX 1 Lung (NSCLC) 1018 Controversy with other publications 203 GTG GTT Val Val SM EKVX 2 Lung (NSCLC) 2249 Controversy with other publications 204 GAG TAG Glu Stop SM EKVX 46 Lung (NSCLC) 2249 Controversy with other publications 47 CCG CTG Pro Leu SM NCI-H1373 3 Lung (NSCLC) 106 Controversy with other publications 34 CCC ins1 Pro Fs. DMU NCI-H157 1 Lung (NSCLC) 1382 Controversy with other publications 282 CGG CCG Arg Pro SM NCI-H157 21 Lung (NSCLC) 2021 Controversy with other publications 298 GAG TAG Glu Stop SM NCI-H157 71 Lung (NSCLC) 92 Controversy with other publications 298 GAG TAG Glu Stop DMU NCI-H157 71 Lung (NSCLC) 1382 Controversy with other publications 285 GAG AAG Glu Lys SM NCI-H1703 165 Lung (NSCLC) 92 Controversy with other publications 209 AGA TGA Arg Stop SM NCI-H1793 14 Lung (NSCLC) 92 Controversy with other publications 273 CGT CAT Arg His SM NCI-H1793 780 Lung (NSCLC) 2249 Controversy with other publications 158 CGC CTC Arg Leu SM NCI-H226 92 Lung (NSCLC) 92 Controversy with other publications 309 CCC GCC Pro Ala SM NCI-H226 1 Lung (NSCLC) 1018 Controversy with other publications 249 AGG AGC Arg Ser SM NCI-H324 34 Lung (NSCLC) 678 Controversy with other publications 249 AGG AGC Arg Ser DMU NCI-H324 34 Lung (NSCLC) 92 Controversy with other publications 259 GAC GTC Asp Val DMU NCI-H324 21 Lung (NSCLC) 92 Controversy with other publications 248 CGG TGG Arg Trp SM PC-14 728 Lung (NSCLC) 1382 Controversy with other publications 248 CGG CAG Arg Gln SM PC-14 883 Lung (NSCLC) 2242 Controversy with other publications 280 AGA AAA Arg Lys SM SK-MES-1 78 Lung (NSCLC) 1081 Controversy with other publications. Excluded from the cosnensus 298 GAG TAG Glu Stop SM SK-MES-1 71 Lung (NSCLC) 303 Consensus based on three publications. Controversy with other publications 46 TCC del1b Ser Fs. DMU NCI-H1048 1 Lung (SCLC) 2249 Controversy with other publications 273 CGT TGT Arg Cys SM NCI-H1048 687 Lung (SCLC) 22 Controversy with other publications 273 CGT TGT Arg Cys DMU NCI-H1048 687 Lung (SCLC) 2249 Controversy with other publications 258 GAA AAA Glu Lys DMU MeWo 73 Melanoma 2249 Controversy with other publications 258 GAA AAA Glu Lys SM MeWo 73 Melanoma 1076 Controversy with other publications 317 CAG TAG Gln Stop DMU MeWo 25 Melanoma 2249 Controversy with other publications 341 TTC TTT Phe Phe SM MeWo 4 Melanoma 2019 Controversy with other publications 342 CGA TGA Arg Stop SM MeWo 74 Melanoma 2019 Controversy with other publications 239 AAC GAC Asn Asp SM PA-1 53 Ovarian carcinoma 854 Controversy with other publications. wt in COSMIC 316 CCC CCT Pro Pro SM PA-1 6 Ovarian carcinoma 144 Controversy with other publications. wt in COSMIC 89 CCC del1a Pro Fs. SM SK-OV-3 3 Ovarian carcinoma 2249 Controversy with other publications 179 CAT CGT His Arg SM SK-OV-3 146 Ovarian carcinoma 1018 Controversy with other publications 262 GGT GTT Gly Val SM SW626 14 Ovarian carcinoma 864 Controversy with other publications 273 CGT CAT Arg His SM SW626 780 Ovarian carcinoma 1011 Controversy with other publications 134 TTT del1a Phe Fs. SM AsPC-1 4 Pancreatic cancer 397 Consensus based on four publications. Controversy with other publications 273 CGT CAT Arg His SM ASPC-1 780 Pancreatic cancer 132 Controversy with other publications. Excluded from the consensus 273 CGT CAT Arg His SM Panc-1 780 Pancreatic cancer 178 Consensus based on four publications. Controversy with one publication 273 CGT TGT Arg Cys SM Panc-1 687 Pancreatic cancer 177 Controversy with other publications. Excluded from the cosnensus 223 CCT CTT Pro Leu DMD DU-145 5 Prostate ca. 59 Consensus based on three publications. Controvery withy other publications (only one of the two mutations is found) 274 GTT TTT Val Phe DMD DU-145 32 Prostate ca. 59 Consensus based on three publications. Controvery withy other publications (only one of the two mutations is found) 278 CCT GCT Pro Ala DMU 786-0 24 Renal cell ca. 1018 Controversy with other publications. Splice in COSMIC 273 CGT TGT Arg Cys SM Rh30 687 Rhabdomyosarcoma 1190 Controversy with other publications 280 AGA AGT Arg Ser SM RH30 14 Rhabdomyosarcoma 97 Controversy with other publications 111 CTG GTG Leu Val SM MOLT-4 1 T-cell Acute Lymphoblastic Leu 2242 Controversy with other publications 248 CGG CAG Arg Gln SM MOLT-4 883 T-cell Acute Lymphoblastic Leu 27 Controversy with other publications 306 CGA TGA Arg Stop SM MOLT-4 160 T-cell Acute Lymphoblastic Leu 2249 Controversy with other publications

Gastric carcinoma

Table I : cell lines with wt p53

Cell line	ATCC	Reference
SNU-520		747
SNU-719		747
NUGC-4		462
STKM-2		1006
MKN-45		462
MKN-74		462

Table II : cell lines with p53 gene deletion or rearrangement

Cell line	ATCC	Reference
KATO III	HTB-103

Table III : cell lines with p53 splice mutation
(exonic mutations that modify splice are listed in table IV)

No data

Table IV: cell lines with p53 mutations (missense or frameshift)
More information is available in the handbook

Pos: Codon position (1 to 393);
WT: Normal base sequence of the codon in which the mutation occurred;
Mut Sequence of the mutated codon. If the mutation is a deletion or an insertion, it is indicated by "del" or "ins" followed by the number of deleted or inserted bases. The position in the codon is indicated by “a”, “b”, or “c” for the first, second or third base of the codon respectively. Example: "del66b" is a deletion of 66 bases including the second base of the codon; "ins4a" is an insertion of 4 bases occurring between the first and the second base of the codon. Label a, b, or c is omitted if the boundary of the deletion or insertion is unknown
AA: Wild type amino acid;
Mut: Mutant amino acid. Stop: nonsense mutation: Fs.: Frameshift mutation: InF: In-frame insertion or deletion;
Comp: complexity of the mutation: SM: Single mutational event in the tumor; DMU (Double Mutation Unknown): Two p53 mutations in the same tumor but their allelique distribution is unknown; DMD (Double Mutation Different allele): Two p53 mutations in the same tumor on two different p53 alleles; DMS (Double Mutation Same allele): Two p53 mutations in the same tumor on the same p53 allele: MM (Multiple Mutation): More than two p53 mutations in the same tumor;
NB: Number of tumors with this particular mutant in the database;
Ref: reference number;
Comments: information;

Table of references (available also in the handbook)

Pos.	WT	Mut	AA	Mut	Comp	Name	NB	Ref	Comments
248	CGG	TGG	Arg	Trp	SM	20M	728	71	Single report
282	CGG	TGG	Arg	Trp	SM	AKG	600	1393	Single report
307	GCA	del7b	Ala	Fs.	SM	ECC4	1	2249	Mutation in COSMIC database
175	CGC	CAC	Arg	His	SM	G42LATE	1187	1393	Single report
11	GAG	CAG	Glu	Gln	DMU	GCIY	10	2249	Mutation in COSMIC database
179	CAT	CAG	His	Gln	DMU	GCIY	14	2249	Mutation in COSMIC database
104	CAG	TAG	Gln	Stop	SM	GT3TKB	18	2249	Mutation in COSMIC database
145	CTG	CGG	Leu	Arg	SM	H-111	10	1689	Single report
273	CGT	TGT	Arg	Cys	SM	H-162	687	1689	Single report
128	CCT	del37	Pro	Fs.	SM	H-30	2	1689	Single report
272	GTG	ATG	Val	Met	SM	H-55	105	1689	Single report
152	CCG	ins1c	Pro	Fs.	SM	HGC-27	2	2249	Mutation in COSMIC database
245	GGC	AGC	Gly	Ser	SM	HSC-39	440	2087	Single report
193	CAT	CCT	His	Pro	SM	HUG-1N	18	2242	Single report
173	GTG	ATG	Val	Met	SM	JR1	77	94	Single report
173	GTG	GCG	Val	Ala	SM	KWS	20	94	Single report
143	GTG	GCG	Val	Ala	SM	MKN-1	20	71	Confirmed in another publication
251	ATC	CTC	Ile	Leu	SM	MKN-28	5	94	Single report
278	CCT	TCT	Pro	Ser	SM	MKN-7	87	2087	Single report
251	ATC	CTC	Ile	Leu	DMU	MKN-74	5	1006	Controversy with other publications. wt in COSMIC
251	ATC	CTC	Ile	Leu	SM	MKN-74	5	94	Controversy with other publications. wt in COSMIC
271	GAG	GCG	Glu	Ala	DMU	MKN-74	3	1006	Controversy with other publications. wt in COSMIC
248	CGG	CAG	Arg	Gln	SM	NCI-N87	883	46	Single report
220	TAT	TGT	Tyr	Cys	SM	NUGC-3	336	94	Confirmed in another publication
342	CGA	TGA	Arg	Stop	SM	OKAJIMA	74	71	Single report
57	GAC	del17	Asp	Fs.	SM	SK-GT-1	2	462	Single report
175	CGC	CAC	Arg	His	SM	SK-GT-2	1187	462	Single report
281	GAC	GAG	Asp	Glu	SM	SK-GT-5	26	462	Single report
205	TAT	TTT	Tyr	Phe	SM	SNU-16	3	46	Single report
216	GTG	ATG	Val	Met	SM	SNU-216	74	747	Single report
266	GGA	GAA	Gly	Glu	SM	SNU-484	74	747	Single report
143	GTG	del1	Val	Fs.	SM	SNU-55	2	46	Single report
273	CGT	CAT	Arg	His	SM	SNU-601	780	747	Single report
282	CGG	TGG	Arg	Trp	SM	SNU-638	600	747	Single report
215	AGT	AAT	Ser	Asn	SM	SNU-668	15	747	Single report
273	CGT	TGT	Arg	Cys	DMU	TGBC11TKB	687	2249	Mutation in COSMIC database
381	AAA	del1a	Lys	Fs.	DMU	TGBC11TKB	1	2249	Mutation in COSMIC database
173	GTG	ATG	Val	Met	SM	TMK-1	77	71	Confirmed in another publication
175	CGC	CAC	Arg	His	SM	YCC-3	1187	46	Single report